HC Wainwright Brokers Lower Earnings Estimates for ABEO

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at HC Wainwright dropped their Q1 2025 EPS estimates for shares of Abeona Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.36) per share for the quarter, down from their previous forecast of ($0.34). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19.

Several other analysts have also recently issued reports on ABEO. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.00 on Wednesday. The firm has a market cap of $217.36 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $5.43 and its two-hundred day moving average is $5.82. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $8.45.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ABEO. Twinbeech Capital LP bought a new position in shares of Abeona Therapeutics in the 4th quarter worth about $58,000. Squarepoint Ops LLC bought a new position in Abeona Therapeutics in the fourth quarter worth about $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics in the third quarter valued at approximately $84,000. Oxford Asset Management LLP bought a new position in shares of Abeona Therapeutics during the fourth quarter valued at approximately $118,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $151,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.